NASDAQ: ACONAclarion Inc Stock
$2.70-0.12 (-4.26%)
Updated Feb 4, 2026
ACON Price
$2.70
Fair Value Price
N/A
Market Cap
$1.81M
52 Week Low
$2.52
52 Week High
$229.50
P/E
0x
P/B
0.15x
P/S
64.72x
PEG
N/A
Dividend Yield
N/A
Revenue
$67.48k
Earnings
-$7.33M
Gross Margin
-7.8%
Operating Margin
-10,867.45%
Profit Margin
-10,948.2%
Debt to Equity
0.06
Operating Cash Flow
-$6M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ACON Overview
Aclarion, Inc. develops software applications for magnetic resonance spectroscopy. It offers the NOCISCAN-LS Post-Processor suite made up of NOCICALC-LS that calculates levels of degenerative pain biomarkers, and NOCIGRAM-LS, clinical decision support software. The company was known as Nocimed, Inc. until 2021/12. Aclarion, Inc. was founded in 2008 and is based in San Mateo, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACON's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
ACON
Ranked#39 of 44
Ranked#39 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.06 | A | |
| $125.10 | A | |
| $11.02 | A |
Be the first to know about important ACON news, forecast changes, insider trades & much more!
ACON News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACON is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ACON is good value based on its book value relative to its share price (0.15x), compared to the US Health Information Services industry average (3.42x)
P/B vs Industry Valuation
ACON is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ACON due diligence checks available for Premium users.
Valuation
ACON price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
26.77x
Market
41.75x
ACON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.15x
Industry
3.42x
ACON is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACON's financial health
Profit margin
Revenue
$18.9k
Net Income
-$1.7M
Profit Margin
-9,008%
ACON's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ACON's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.2M
Liabilities
$699.7k
Debt to equity
0.06
ACON's short-term assets ($11.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACON's short-term assets ($11.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
-$40.2k
Financing
-$283.8k
ACON's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACON vs Health Information Service Stocks
Aclarion Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.